Andy Obermueller
Government-Driven Investing
Keith Fitz-Gerald
New China Trader
Marvin Appel
Systems & Forecasts
Jim Powell
Global Changes & Opportunities Report

Healthy outlook for Pfizer (PFE)


Bookmark and Share

 "I'm boosting my stake in Pfizer (NYSE: PFE); its merger with Wyeth created a firm with one of the broadest and deepest portfolios in the drug industry," says Ian Wyatt in The Recovery Portfolio.

Advertisement
Banner

"Like many of its peers, Pfizer faces massive patent losses on key drugs in coming years. Most notably, Lipitor, which is the largest selling anti-cholesterol drug in the world, loses U.S. patent exclusivity in 2011.

"But the addition of Wyeth's drug portfolio, coupled with an estimated $4 billion in merger synergies, should help Pfizer offset this loss. 

"And Pfizer's current share price already reflects the major risks faced by the company. Trading at only 8x estimated 2010 earnings, Pfizer's valuation is among the lowest in the entire pharmaceuticals universe. 

"The company's generous 3.6% dividend yield should also provide support for the stock, especially if 2010 turns out to be a listless, sideways-trending market.

"Finally, much has been made about the possible effects of healthcare reform on the business of companies like Pfizer. In my view, there's little doubt that reform will pressure drug prices lower over the long term. 

"At the same time, reform will likely be a net positive for the industry, as million of currently underinsured Americans gain coverage. Plus, nearly 60% of Pfizer's revenues come from international operations, which will be unaffected by the U.S. reform debate."




News Flash

Geron (GERN)
Steve Christ, The Wealth Advisory

In a recent 15-page ruling, a U.S. judge ruled that using taxpayer dollars to fund embryonic stem cell research violates a 1996 law; but in the case of Geron Corp. (GERN), the company won’t be affected at all.


Read more...

 

Industrial trio: BWA, TEN, DXPE
Stephen Quickel, US Investment Report

Among our new stock are three industrials that expected to grow earnings by 30% a year: Borg Warner (BWA), Tenneco (TEN) and DXP Enterprises (DXPE).


Read more...


Banner
Banner
   

Bullion Monarch Mining (BULM)
Max Bowser, The Bowser Report

Bullion Monarch Mining (BULM) -- a holding in our "penny stock" portfolio -- recorded its best revenue year ever.


Read more...

 

Global X Lithium ETF (LIT)
Jim Trippon, ETF Profit Report

It’s rare that we would recommend an ETF that is as new as Global X Lithium (LIT), but with the market taking a tumble, we believe we’re getting good value on this newly-minted vehicle.


Read more...

 

Consumer Staples (XLP)
by Doug Fabian, Making Money Alert

The Consumer Staples Select Sector SPDR (XLP) is an ETF that tracks companies that have products that people need in both good and bad economic times.


Read more...

 

WisdomTree SmallCap Dividend (DES)
by Walter Frank, MoneyLetter

WisdomTree SmallCap Dividend (DES), which sports an attractive 4.3% yield, has been added to our fund coverage.


Read more...

 

Closed-end income favorites
by Harry Domash, Dividend Detective

The latest new positions in our closed-end fund portfolio are Guggenheim Emerging Opportunity (GOF) and First Trust/Aberdeen Emerging Opportunity (FEO).


Read more...

 

Quality trio: XOM, GOOG, JNJ
by Adam Sharp, contributing editor Wealth Daily

Buying defensive blue chips makes sense. Three of my favorites are ExxonMobil (XOM), Johnson and Johnson (JNJ) and Google (GOOG).


Read more...

 

Xcel Energy (XEL)
by Roger Conrad, The Utility Forecaster

In late 2002 Xcel Energy (XEL) was on the brink of Chapter 11; it has since come back, recently earning a credit upgrade from S&P to A- with an "excellent" risk profile.


Read more...

 

Virginia Mines (VGQ)
by Adrian Day, The Global Analyst

Virginia Mines (VGQ) remains one of a handful of my favorite companies; the company continues ongoing rationalization of its extensive mining property portfolio.


Read more...